掻痒(Pruritus):治療薬開発パイプライン動向(2015年上半期版)

◆英語タイトル:Pruritus - Pipeline Review, H1 2015
◆商品コード:GMDHC6350IDB
◆発行会社(調査会社):Global Markets Direct
◆発行日:2015年2月28日
◆ページ数:91
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥226,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥678,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。
当調査レポートでは、世界における掻痒(Pruritus)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。

・イントロダクション
・掻痒(Pruritus)の概要
・掻痒(Pruritus)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・掻痒(Pruritus)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・製品
・大学/研究機関別、研究中の製品
・掻痒(Pruritus)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・掻痒(Pruritus)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Pruritus – Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Pruritus – Pipeline Review, H1 2015’, provides an overview of the Pruritus’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Pruritus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pruritus and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Pruritus
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Pruritus and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Pruritus products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Pruritus pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Pruritus
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Pruritus pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Pruritus Overview 8
Therapeutics Development 9
Pipeline Products for Pruritus – Overview 9
Pipeline Products for Pruritus – Comparative Analysis 10
Pruritus – Therapeutics under Development by Companies 11
Pruritus – Therapeutics under Investigation by Universities/Institutes 13
Pruritus – Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Pruritus – Products under Development by Companies 17
Pruritus – Products under Investigation by Universities/Institutes 19
Pruritus – Companies Involved in Therapeutics Development 20
AlbireoPharma 20
Amorepacific Corporation 21
Cara Therapeutics, Inc. 22
Conrig Pharma ApS 23
Creabilis SA 24
ELORAC, Inc. 25
FAES Farma SA 26
GlaxoSmithKline plc 27
Helsinn Holding S.A. 28
Hydra Biosciences, Inc. 29
LEO Pharma A/S 30
Merck & Co., Inc. 31
NeRRe Therapeutics Ltd 32
Nippon Shinyaku Co., Ltd. 33
RDD Pharma Ltd. 34
Shionogi & Co., Ltd. 35
Tioga Pharmaceuticals, Inc. 36
Trevi Therapeutics, Inc. 37
Vanda Pharmaceuticals Inc. 38
Pruritus – Therapeutics Assessment 39
Assessment by Monotherapy Products 39
Assessment by Target 40
Assessment by Mechanism of Action 42
Assessment by Route of Administration 44
Assessment by Molecule Type 46
Drug Profiles 48
A-4250 – Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
aprepitant – Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
asimadoline – Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
ASN-008 – Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
bilastine – Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
C-746 – Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
CR-845 – Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
CRG-010 – Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
CT-327 – Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
desloratadine – Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Drugs to Target Mas-Related G-Protein Coupled Receptor for Pruritus – Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
GSK-2330672 – Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
nalbuphine hydrochloride ER – Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
naloxone hydrochloride – Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
netupitant – Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
NS-141 – Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
orvepitant maleate – Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
PAC-14028 – Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
PP-120 – Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
serlopitant – Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Small Molecule for Pruritus Ani – Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Small Molecule to Agonize CB2 for Pruritus – Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Small Molecules to Antagonize TRPV3 for Pruritus and Psoriasis – Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Small Molecules to Block NaV1.7 Channel for Pain and Pruritus – Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
tradipitant – Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Pruritus – Recent Pipeline Updates 79
Pruritus – Dormant Projects 88
Pruritus – Discontinued Products 89
Appendix 90
Methodology 90
Coverage 90
Secondary Research 90
Primary Research 90
Expert Panel Validation 90
Contact Us 90
Disclaimer 91

[List of Tables]
Number of Products under Development for Pruritus, H1 2015 9
Number of Products under Development for Pruritus - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 12
Number of Products under Investigation by Universities/Institutes, H1 2015 13
Comparative Analysis by Late Stage Development, H1 2015 14
Comparative Analysis by Clinical Stage Development, H1 2015 15
Comparative Analysis by Early Stage Development, H1 2015 16
Products under Development by Companies, H1 2015 17
Products under Development by Companies, H1 2015 (Contd..1) 18
Products under Investigation by Universities/Institutes, H1 2015 19
Pruritus - Pipeline by AlbireoPharma, H1 2015 20
Pruritus - Pipeline by Amorepacific Corporation, H1 2015 21
Pruritus - Pipeline by Cara Therapeutics, Inc., H1 2015 22
Pruritus - Pipeline by Conrig Pharma ApS, H1 2015 23
Pruritus - Pipeline by Creabilis SA, H1 2015 24
Pruritus - Pipeline by ELORAC, Inc., H1 2015 25
Pruritus - Pipeline by FAES Farma SA, H1 2015 26
Pruritus - Pipeline by GlaxoSmithKline plc, H1 2015 27
Pruritus - Pipeline by Helsinn Holding S.A., H1 2015 28
Pruritus - Pipeline by Hydra Biosciences, Inc., H1 2015 29
Pruritus - Pipeline by LEO Pharma A/S, H1 2015 30
Pruritus - Pipeline by Merck & Co., Inc., H1 2015 31
Pruritus - Pipeline by NeRRe Therapeutics Ltd, H1 2015 32
Pruritus - Pipeline by Nippon Shinyaku Co., Ltd., H1 2015 33
Pruritus - Pipeline by RDD Pharma Ltd., H1 2015 34
Pruritus - Pipeline by Shionogi & Co., Ltd., H1 2015 35
Pruritus - Pipeline by Tioga Pharmaceuticals, Inc., H1 2015 36
Pruritus - Pipeline by Trevi Therapeutics, Inc., H1 2015 37
Pruritus - Pipeline by Vanda Pharmaceuticals Inc., H1 2015 38
Assessment by Monotherapy Products, H1 2015 39
Number of Products by Stage and Target, H1 2015 41
Number of Products by Stage and Mechanism of Action, H1 2015 43
Number of Products by Stage and Route of Administration, H1 2015 45
Number of Products by Stage and Molecule Type, H1 2015 47
Pruritus Therapeutics - Recent Pipeline Updates, H1 2015 79
Pruritus - Dormant Projects, H1 2015 88
Pruritus - Discontinued Products, H1 2015 89

[List of Figures]
Number of Products under Development for Pruritus, H1 2015 9
Number of Products under Development for Pruritus - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 11
Comparative Analysis by Clinical Stage Development, H1 2015 15
Comparative Analysis by Early Stage Products, H1 2015 16
Assessment by Monotherapy Products, H1 2015 39
Number of Products by Top 10 Targets, H1 2015 40
Number of Products by Stage and Top 10 Targets, H1 2015 41
Number of Products by Top 10 Mechanism of Actions, H1 2015 42
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 43
Number of Products by Top 10 Routes of Administration, H1 2015 44
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 45
Number of Products by Top 10 Molecule Types, H1 2015 46
Number of Products by Stage and Top 10 Molecule Types, H1 2015 47

【掲載企業】

AlbireoPharma
Amorepacific Corporation
Cara Therapeutics, Inc.
Conrig Pharma ApS
Creabilis SA
ELORAC, Inc.
FAES Farma SA
GlaxoSmithKline plc
Helsinn Holding S.A.
Hydra Biosciences, Inc.
LEO Pharma A/S
Merck & Co., Inc.
NeRRe Therapeutics Ltd
Nippon Shinyaku Co., Ltd.
RDD Pharma Ltd.
Shionogi & Co., Ltd.
Tioga Pharmaceuticals, Inc.
Trevi Therapeutics, Inc.
Vanda Pharmaceuticals Inc.

★調査レポート[掻痒(Pruritus):治療薬開発パイプライン動向(2015年上半期版)] (コード:GMDHC6350IDB)販売に関する免責事項を必ずご確認ください。
★調査レポート[掻痒(Pruritus):治療薬開発パイプライン動向(2015年上半期版)]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆